MedPath

Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

Recruiting
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Registration Number
NCT01420562
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
55
Inclusion Criteria
  • Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections
Exclusion Criteria
  • Gastroparesis
  • Vomiting or diarrhea within 2 hours after intake of posaconazole
  • Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...
  • Age under 18 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Posaconazole plasma levels and area under the curve in patients with different stages of mucositisDay 0 (day of transplantation), day +7, day +14

Plasma levels of posaconazole will be determined to calculate the area under the curve. These values will be correlated with the stage of mucositis, which will be assessed using citrulline monitoring in plasma. The stage of mucositis will also be assessed using the Daily Oral Mucositis Score (DMS) and Daily Gut Mucositis Score (DGS).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospitals Leuven

🇧🇪

Leuven, Vlaams-Brabant, Belgium

University Hospitals Leuven
🇧🇪Leuven, Vlaams-Brabant, Belgium
Kim Vanstraelen, R.Ph.
Principal Investigator
Isabel Spriet, Pharm.D.
Sub Investigator
Ludo Willems, Professor
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.